Posted by Michael Wonder on 26 May 2017
Hepatera: eligibility to PRIME scheme granted to Myrcludex B by the European Medicines Agency
25 May 2017 - MYR and its development partner Hepatera today announced that the EMA granted "PRIME eligibility" for Myrcudex B, a first in class entry inhibitor for Hepatitis Delta (D) virus.
Myrcludex B is a first in class entry inhibitor for treatment of chronic hepatitis B and D. The drug has shown promising efficacy in Phase 2a trials. Recruitment for Phase 2b program in HDV is completed.
